NCT00911092已完成4 期
Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 12
- 主要终点
- Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry
研究概览
简要总结
The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.
详细描述
Further informations will be provided by Centre Oscar Lambret.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven
- •Treated by exclusive concomitant radiochemotherapy
- •Written informed consent
排除标准
- •Presence of a second uncontrolled cancer
- •Metastatic carcinoma
- •Metastatic disease, except cervical lymphnodes... (M1a)
- •In situ carcinoma
- •Eso-gastric junction cancer (Siewert II ou III)
- •Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)
结局指标
主要结局
Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry
时间窗: 15 weeks after the end of irradiation
Initial complete clinical response
时间窗: 15 weeks after the end of irradiation
次要结局
- Prolonged clinical response at one year(One year after the end of irradiation)
研究者
研究点 (12)
Loading locations...
相似试验
终止
不适用
Biochemical Makers for Outcome After Pediatric out-of Hospital Cardiac ArrestOut-Of-Hospital Cardiac ArrestNCT03873662Brno University Hospital4
已完成
不适用
Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological OutcomeCardiac ArrestNCT02247947Universitätsklinikum Köln20
已完成
4 期
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel DiseaseInflammatory Bowel DiseasesUlcerative ColitisCrohn DiseaseNCT03885713Fundación de Investigación Biomédica - Hospital Universitario de La Princesa180
尚未招募
不适用
To identify if there are any clinical or immunological markers that can help us predict disease relapse in a patient. This knowledge can help the physicians to decide when to administer the maintenance treatment to prevent clinical relapse.CTRI/2020/10/028675All India Institute of Medical Sciences
已完成
3 期
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.Immune Thrombocytopenic PurpuraAutoimmune ThrombocytopeniaThrombopeniaNCT04070599University Hospital, Bordeaux70